Gilde Healthcare anchors $103.5 million public offering by Affimed - Gilde Healthcare

Gilde Healthcare anchors $103.5 million public offering by Affimed

April 21, 2022
Utrecht (the Netherlands)

Gilde announces that it acted as anchor investor in an upsized $103.5 million public offering by German immune-oncology company Affimed N.V. (Nasdaq: AFMD) (“Affimed”). As a result, Gilde’s ownership exceeds 5% of the outstanding share capital of Affimed.

“We are excited to team up with the excellent team at Affimed, who are front-runners in engaging the innate immune system to fight some of the most difficult-to-treat cancers,” said Joep Muijrers, General Partner at Gilde Healthcare and responsible for Gilde’s public investment franchise. “We are proud to add Affimed to our expanding portfolio, and look forward to closely working with them in the years to come”.

Pieter van der Meer, Managing Partner of Gilde Healthcare commented “We followed Affimed for many years and are convinced about the potential of its technology platform and immune oncology product pipeline. By anchoring the public offering we enabled a transformational financing in a turbulent market environment, reflecting our impactful, hands-on investment strategy.”

The full text of the announcement from Affimed can be found here:
Affimed announces closing of public offering of common shares and full exercise of underwriters’ option to purchase additional shares – Affimed.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor with two fund strategies: Venture&Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in fast growing, innovative companies active in (bio)pharmaceuticals, healthtech and medtech that are based in Europe and North America. For more information, please visit

First Enrolment in the ProVIDE Clinical Study for BPH Treatment

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the commencement of the ProVIDE pivotal clinical trial to evaluate the...
June 10, 2022

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds...
May 20, 2022

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...
May 19, 2022